Group 1 - The core viewpoint of the news is that the Shanghai Stock Exchange 300 Pharmaceutical Index has shown significant growth, with a 5.11% increase over the past month, 8.47% over the past three months, and 11.75% year-to-date [1] - The Shanghai Stock Exchange 300 Pharmaceutical Index is composed of listed companies in the pharmaceutical sector selected from the Shanghai and Shenzhen 300 Index, reflecting the overall performance of these companies [1] - The index was established on December 31, 2004, with a base value of 1000.0 points [1] Group 2 - The top ten weighted companies in the Shanghai Stock Exchange 300 Pharmaceutical Index include: Heng Rui Medicine (42.9%), Pian Zai Huang (9.95%), Yunnan Baiyao (8.35%), Kelun Pharmaceutical (6.51%), East China Pharmaceutical (6.41%), Fosun Pharmaceutical (5.58%), New Hecheng (5.56%), Tong Ren Tang (4.09%), Bai Li Tianheng (4.02%), and China Resources Sanjiu (3.51%) [1] - The market share of the index's holdings is 69.65% from the Shanghai Stock Exchange and 30.35% from the Shenzhen Stock Exchange [1] - The composition of the index by industry shows that drug formulations account for 65.43%, traditional Chinese medicine for 29.01%, and raw materials for 5.56% [1] Group 3 - The index sample is adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - Companies that are delisted or undergo mergers, acquisitions, or splits are handled according to specific calculation and maintenance guidelines [2]